Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

How Medicare ‘Self-Referral’ Thrives on Loophole

(Wall Street Journal) Oct 22, 2014 - In a letter to a friend, the manager of a Florida urology practice worried in 2010 that her company would attract federal scrutiny for its frequent use of an expensive bladder-cancer test.

Commentary: As a relatively new 21st Century physician involved in a multimodality cancer practice I have to respond to this...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Medivation and Astellas Announce Phase 3 Study of Enzalutamide in Men With High-Risk, Hormone-Sensitive, Non-Metastatic Prostate Cancer That Has Recurred Following Definitive Local Therapy

(Astellas) Oct 30, 2014 - Medivation Inc. and Astellas today announced plans to initiate a global Phase 3 clinical trial that will evaluate the efficacy and safety of enzalutamide in patients with high-risk, hormone-sensitive, non-metastatic prostate cancer that has biochemically recurred (rising prostate-specific antigen [PSA] level) following definitive local therapy with radical prostatectomy and/or radiation therapy.
read corporate press release »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



How Medicare ‘Self-Referral’ Thrives on Loophole (Wall Street Journal)

As a relatively new 21st Century physician involved in a multimodality cancer practice I have to respond to this...posted by: Thomas Marsland, MD

At Home with the Specialist: Oncologists and Other Specialists Launching Patient-centered Medical Homes (Modern Healthcare)

So the oncology medical home is part of a wider effort to develop new compensation mechanisms that preserve private...posted by: Thomas Marsland, MD

Petition Calls on Roche to Cut Breast Cancer Drug Price (Reuters)

The high cost of drugs today is a significant problem on both sides of the Atlantic. I realize that there are huge...posted by: Thomas Marsland, MD

Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines (StreetInsider.com)

I personally find that the VeriStrat test doesn't answer a question that is especially relevant for most of my...posted by: H. Jack, West, MD

FOLFOXIRI Plus Bevacizumab Ups Outcome in Metastatic CRC (Monthly Prescribing Reference/HealthDay News)

It is notable that this study accrued patients bewteen 7/08-5/11. The 31 month median overall survival is heartening....posted by: Richard Goldberg, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


NCCN has posted 1 new job.


Bayer Biopharmaceuticals, Inc. has posted 20 jobs.


Ipsen Biopharmaceuticals, Inc. has posted over 50 jobs.


View OBR Job Board>>


GH_edutorial_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
ONCY +14.37%
ZIOP +8.82%
INCY +7.65%
OMED -5.28%
AGEN -5.18%
BIND -5.15%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: September / October 2014
Company: Seattle Genetics / Takeda
Product: Adcetris® (brentuximab vedotin)

Date: Q4 2014
Company: Bristol-Myers Squibb / Ono Pharmaceutical Co.
Product: Opdivo® (nivolumab)

Date: December 5, 2014
Company: Novartis / Incyte Corp.
Product: Jakafi® (ruxolitinib)

See All OBR Radar items»